Henry Schein Q2 Earnings Surpass Wall Street View On Strong Demand For Dental Products, Reaffirms Annual Forecast

Henry Schein Inc HSIC posts Q2 FY23 sales of $3.10 billion, slightly missing the consensus of $3.11 billion, up 2.3% Y/Y, including 0.2% decrease in local currencies excluding acquisitions, 2.9% growth from acquisitions, and a 0.4% decrease related to foreign currency exchange.

Sales of PPE products and COVID-19 test kits were $163 million, a decrease of $96 million versus the prior-year period, excluding sales of PPE products and COVID-19 test kits, Q2 internal sales growth in local currencies was 3.3% compared with the prior-year period.

Global Dental sales were $2.0 billion, an increase of 5.6% Y/Y. Global Medical sales were $1.0 billion, down 4.6% Y/Y.

Adjusted EPS of $1.31, up 0.8%, beat the estimate of $1.25.

Guidance: Henry Schein reaffirms the FY23 adjusted EPS outlook of $5.18-$5.35, compared to the consensus of $5.27.

The company expects year-over-year growth in diluted EPS to be higher in the fourth quarter than in the third quarter.

2023 sales growth is expected to be approximately 1% to 3% over 2022, unchanged from prior guidance.

Price Action: HSIC stock is down 3.19% at $75.60 on the last check Monday.

Photo via Wikimedia Commons

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!